A randomized, double blind controlled factorial clinical trial of edetate disodium‐based chelation and high‐dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction

HS 2018‐4537
Heart, Diabetes
Shaista Malik, MD, PhD, MPH
UCI Health Susan Samueli Integrative Health Institute, 1202 Bristol St, Costa Mesa, CA 92626

In this NIH sponsored study, we will find out if chelation therapy, which reduces levels of heavy metals in the blood can decrease cardiovascular events. In an earlier study of chelation, those with both diabetes and heart disease were found to have a 41% reduction in events with chelation therapy.

In this study, chelation therapy will be given through the vein and study participants will also get oral vitamins and minerals by mouth to lower the risk of new heart problems, including death, another heart attack, chest pain, or heart surgery to open blood vessels.

  • Age of 50 years or older
  • Have had a documented heart attack
  • Have either type 1 or type 2 diabetes
This is a long‐term prevention trial and 40 study visits are required in one year with follow‐up via phone calls for up to five years.
You may receive no direct benefit from being in this study. However, taking part may help you get better care in the future. If you are in the group that receives chelation therapy/EDTA IV and it proves to treat your condition, you may benefit from participating in the study.
$50 per visit, for a total of $2000 for 40 visits.
Ethylenediaminetetraacetic acid (EDTA)
Chelation therapy
Kelly Brink, RN
714‐456‐7025/714-424-9001